Drug General Information (ID: DDIUBM7GCK)
Drug Name			Verteporfin		Drug Info		Ranibizumab (ophthalmic)		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Antineoplastics				Anti-Angiogenic Ophthalmic Agents

Mechanism of Verteporfin-Ranibizumab (ophthalmic) Interaction (Severity Level: Moderate)
Increased risk of other adverse reactions (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Verteporfin				Ranibizumab (ophthalmic)
Mechanism		Oculotoxic effects				Oculotoxic effects
Key Mechanism Factor 1
		Factor Name		Adverse reactions
		Factor Description		An adverse reaction is an unexpected negative reaction to a medication or treatment that happens even when it's used correctly.
Mechanism Description		Increased risk of adverse reactions by the combination of Verteporfin and Ranibizumab (ophthalmic)

Recommended Action
Management		Caution is advised if ranibizumab is coadministered with verteporfin photodynamic therapy.

References
1	Product Information. Lucentis (ranibizumab ophthalmic). Genentech, South San Francisco, CA.